Taken together, these new insights allow the proposition of a classification system that includes (1) leprosy and HIV true coinfection, (2) opportunistic leprosy disease, and (3) leprosy related to highly active antiretroviral therapy.
Pyoderma gangrenosum is an uncommon ulcerative cutaneous dermatosis associated with a variety of systemic diseases including inflammatory bowel disease, arthritis, hematological malignancies, hepatitis and acquired immunodeficiency syndrome (AIDS). The pathogenesis of pyoderma gangrenosum remains unknown. Its diagnosis is usually based on clinical evidence and confirmed through a process of elimination of the other possible causes of cutaneous ulcers. This report describes a case of pyoderma gangrenosum with extensive ulceration that responded well to treatment. Keywords: Diagnosis; Primary Treatment; Pyoderma gangrenosum Resumo: Pioderma gangrenoso é uma dermatose cutânea ulcerativa incomum, associada a uma variedade de doenças sistêmicas, incluindo doença inflamatória intestinal, artrites, neoplasias hematológi-cas, hepatites e aids. A sua patogênese é desconhecida. O diagnóstico geralmente é baseado em evidên-cias clínicas e confirmado com a exclusão das outras etiologias de lesões ulceradas cutâneas. Relatamos um caso de PG com ulcerações extensas com boa resposta ao tratamento.
Abstract:A 21-year-old female presenting linear IgA and IgG disease initially responded well to dapsone therapy. However, the treatment with dapsone was withdrawn due to severe anemia induced by malaria, which led to worsening of the clinical picture. Although prednisone and methylprednisolone were tried, the patient responded only to the association of dapsone and mycophenolate mofetil. Keywords: Dapsone; Immunoglobulin A; Immunoglobulin G; Receptors, IgGResumo: Relata-se o caso de pacien te femi ni na, de 21 anos, com der ma to se por IgA e IgG linear. Inicialmente, a res pos ta clí ni ca foi favo rá vel à dap so na. Após a inter rup ção desta medi ca ção, por crise de ane mia sin to má ti ca, pre ci pi ta da por malá ria, houve piora da doen ça, ape sar da uti li za ção da pred ni so na e pul so te ra pia com metilpred ni so lo na. A rein tro du ção da dap so na, asso cia da ao mico fe no la to mofe til, pos si bi li tou o con tro le da enfermi da de. ©2011 by Anais Brasileiros de Dermatologia INTRO DUC TIONLinear IgA der ma to sis (LAD) is defi ned as an acqui red autoim mu ne bul lous disea se, cha rac te ri zed by linear depo si tion of IgA along the base ment membra ne zone (BMZ). 1,2 Despite the dif fi cul ties in dis tinguis hing sube pi der mal bul lous disea ses, as of 1979 LAD has been dif fe ren tia ted from her pe ti form der mati tis. Since then, bul lous disea ses with sube pi der mal clea va ge and linear depo si tion of IgA along the BMZ have been auto ma ti cally clas si fied as LAD. 3,4 In 1998, Honokik and cols demons tra ted the pre sen ce of IgG against cir cu la ting epi der mal anti gens in LAD patients. 5 Subsequent reports cor ro bo ra te the findings of this group. 3,[6][7][8] The pre sen ce of simul ta neous linear depo si tion of IgA and IgG was fun da men tal for the con cep tion of a new cli ni cal-patho lo gi cal entity, IgA and IgG linear der ma to sis (LAGD). 9,10 However, the mag ni tu de and cli ni cal rele van ce of this clas si fi ca tion remain con trover sial, as there seems to be no dif fe ren ces in the derma to lo gi cal pre sen ta tion and the ra peu tic spec trum of both disea ses. The rea son for such simi la rity has been attri bu ted to the fact that IgA is an anti body with very hete ro ge neous tar get anti gens, against seve ral BM com po nents. A pos si ble mecha nism of inter mo le cu lar expan sion of epi to pes could be res pon si ble for the autoim mu nity exten sion of BP180 anti gen to the
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.